Company profile
Tango Therapeutics, Inc.
NASDAQ:TNGXBiotechnology: Pharmaceutical Preparations
Drug pipeline (2)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| Daraxonrasib | approved | — | 13 | approved |
| Zoldonrasib | phase1_2 | — | 4 | active |
Revenue is the latest reported period from SEC filings. A combination product's amount appears on each of its constituent assets, so those rows are not additive.
Clinical trials (6)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT06810544 | phase1_2 | recruiting | 2025-03-24 | 2027-03-31 | Tango Therapeutics, Inc. | Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss |
| NCT05732831 | phase1_2 | recruiting | 2023-05-26 | 2026-05-01 | Tango Therapeutics, Inc. | Safety and Tolerability of TNG462 in Patients With MTAP-deleted Solid Tumors |
| NCT05275478 | phase1_2 | terminated | 2022-03-23 | 2025-12-30 | Tango Therapeutics, Inc. | Safety and Tolerability of TNG908 in Patients With MTAP-deleted Solid Tumors |
| NCT05887492 | phase1_2 | active_not_recruiting | 2023-06-12 | 2026-09-01 | Tango Therapeutics, Inc. | Study of TNG260 and an Anti-PD Antibody in STK11 Mutated Solid Tumors |
| NCT06065059 | phase1_2 | terminated | 2023-12-08 | 2024-05-22 | Tango Therapeutics, Inc. | Study to Evaluate TNG348 Alone and With a PARP Inhibitor in Patients With BRCA 1/2 Mutant or HRD+ Solid Tumors |
FDA applications (0)
No records yet.